Longevity Economics Institute

Can Family Offices Be a Factor in Longevity Biotech? Family offices invest heavily in healthcare and life sciences. According to a Goldman Sachs survey, 34% of these funds are “overweight” in healthcare, meaning they invest more in this sector relative to the market benchmark. This underscores a strong preference for life sciences opportunities. A key advantage of family offices is their ability to withstand biotech’s volatility, as highlighted in Crain Currency article. Their generational perspective can encourage long-term investment horizons—typically longer than those of institutional investors or traditional venture capital firms. This is vital because biotech breakthroughs can take decades. Their motivations often stem from personal experiences of a family member (such as exposure to a specific disease) and a desire to make a significant impact. Interestingly, unlike donations, investments from family offices, according to Crain, can spur progress more effectively. In longevity biotech family offices typically invest into businesses closer to the market like longevity clinics or supplements—businesses that generate cash more quickly. Generally, family offices aim to preserve wealth rather than aggressively grow it. A notable exception is Apeiron Investment Group, led by Christian Angermayer, which has holdings in Centenara Labs AG and Cambrian Bio. Some family offices also donate to institutions like the Buck Institute for Research on Aging. We expect growing family office interest in longevity biotechnology as the field matures. We at Longevity Economics Institute are helping family offices to navigate this emerging field. References https://lnkd.in/gwqTbdQ6 https://lnkd.in/gXSzjCHK

Ministry of Foreign Affairs, Saudi Arabia has APPROVED my visa in just one day, all through a fully online process (unlike their myopic counterparts at U.S. Department of State with rejections and 20+ year old glitchy software). What the Saudi government has also approved is the Hevolution Foundation - $1B/year commitment to extend healthy human lifespans. It looks like for now Saudi Arabia and Singapore are the only countries that really get where the puck is going (and yes, it’s longevity biotech). See everyone at Global Healthspan Summit 4-5 Feb 2025! I am going to share what our plans are at Longevity Economics Institute.

Longevity biotechnology has the potential to become one of the most valuable industries in the world. Additional years of life might place a greater burden on society (think of the “gray tsunami” narrative) or might deliver tremendous benefits if those extra decades are spent in great cognitive and physical health. How much value is at stake? This is exactly what the Longevity Economics Institute specializes in. We’re also exploring how to measure this value, how to select the most efficient ways to allocate resources, how to approach valuation of longevity biotech startups, and other related questions. If you like what we do - follow us and invite your friends, provide feedback, collaborate, share our content.

I've been digging into Andrew J Scott and Julian Ashwin paper. There's an interesting table that models a theoretical case of a therapy, applied once a year, that regenerates either 1 year, 9 months, 6 months, and 3 months of aging at different ages (see the table). So reversing one year of aging per year is essentially the Longevity Escape Velocity point. In this scenario, the expected lifespan for 30-year-olds is 1,782.6 years. Way better than now! But there are important nuances (I played around with the data for you): 1️⃣ When we remove aging from the equation, there are still chances of dying (from infections, violence, accidents, and cancers). For 30-year-olds, the mortality rate in the paper is about ~0.057% per year, which corresponds to data from developed countries (for example, similar to Japan). 2️⃣ There's a huge variation in lifespan (see the survival curve I modeled based on the same data): - Half the people will die before reaching 1,214.5 years - 18% will live up to 3,000 years - 5.78% will make it to 5,000 years - 0.33% will reach 10,000 years 3️⃣ We also know there are big differences between male and female mortality rates. I found the mortality rates for 25-year-olds in Japan (0.02% for women, 0.04% for men) and plotted a graph (see the graph with two curves). What do we observe: - It's way better to be a woman! - If you're a man lucky enough to live to 5,000 years, you're in a world where there are three 25-year-old Japanese women for every one of you! - If you're a man and you've made it to 10,000 years, the number of 25-year-old Japanese women per man is ~7.5. Is it just me, or am I uncovering new reasons to pursue radical life extension? (Of course we are talking about biological age in theoretical high calendar-year-old 25-year-olds!) Subscribe for Longevity Economics Institute - we are working on a lot of interesting analytics! Paper for the reference https://lnkd.in/dzZvRtM9

Two day ago I was sitting in Berlin Airport after spending the last six weeks co-organizing Zelar City, I wanted to share some thoughts while they're still fresh. Zelar.city is a pop-up city aimed at diving deep into how to accelerate the onset of the future without death and disease. 1️⃣ Living Among Like-Minded People is awesome. It's been absolutely amazing to live among people who share the same passion. The biggest takeaway for me is the deep new friendships with folks who are seriously committed to fighting aging. 2️⃣ I kicked-off Several Projects I kicked off a small project and am working on a bigger one with people I met there (Welcome Longevity Economics Institute - follow the page. Major announcements are coming soon). Might even start 1–2 more projects. Spending so much time together lets you really understand what everyone's capable of and whether you can build something together. 3️⃣ The Potential of Pop-Up Cities I think this concept has a lot of promise. Sure, there are limitations (hard to commit for a month or two if you have kids or an offline job), but we've gotten lots of enthusiastic feedback. Some people, after spending a bit of time, even came back for another 1–2 weeks. 4️⃣ General Public is Still More Interested in Health and Supplements Turns out, people are really interested in healthy lifestyles and supplements. Our thematic summits (we organized 1–2 per week) drew the biggest crowds. 5️⃣ Emerging Startups are Focusing on Alternative Approaches Over the past few years, some really interesting startups have popped up—gene therapy, replacement therapies, and a few new companies in cryonics. Getting funding for these kinds of projects is a reason for cautious optimism, but we need to think about how to scale funding by tens or even hundreds of times (Longevity Economics Institute 🚀 ). 6️⃣ Funding as the Bottleneck I believe funding is the biggest bottleneck in our industry. Victoria Forest and Laurence Ion think the biggest issue are the regulations that make bringing new interventions to market much harder. And what do you think?